Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

COMPLETED

Identifier: CI-TRIAL-00098925
Entity page: /trial/NCT02005289 ↗
Edges: 12

Neighbours: 3 cancers2 drugs
Drawn: 5 of 5 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL condition of …CONDITION_OFderived10 of 10
← condition of	Chronic Lymphocytic Leukemia registry condition “Stage III Chronic Lymphocytic Leukemia” mapped CURATED_BROADER	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Chronic Lymphocytic Leukemia registry condition “Stage IV Chronic Lymphocytic Leukemia” mapped CURATED_BROADER

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL intervention of …INTERVENTION_OFderived2 of 2
← intervention of	Lenalidomidesmall molecule registry intervention “lenalidomide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Tafasitamabmonoclonal antibody registry intervention “MOR00208” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL intervention of …INTERVENTION_OFderived2 of 2

← intervention of

Lenalidomidesmall molecule

registry intervention “lenalidomide” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →